Back

Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on arterial stiffness, coronary flow reserve and liver steatosis in diabetes

2 September 2024 (08:00 - 08:50)
Organised by: Logo
Congress Presentation Part of: Diabetes: a risk factor in heart disease Metabolic Syndrome, Insulin, Insulin Resistance ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Konstantinos Katogiannis

Attikon University Hospital, Athens (Greece)

7 More presentations in this session

Presentation thumbnail
Diabetes Mellitus influence in Lipoprotein(a) gene expression and association to coronary artery disease
Doctor D. Sa (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
BMI shift and associated cardiometabolic risk factors in people with type 2 diabetes and obesity and/or overweight: a post hoc analysis from SURMOUNT-2
Doctor N. Sattar (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Social vulnerability and disparities in incidence of diagnosed diabetes in the united states, 2004 to 2019
Doctor S. Ayanian (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Plasma proteomics of all-cause and cause-specific mortality in individuals with and without type 2 diabetes: Results from two population-based KORA cohorts
Miss H. Luo (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Prevalence and incidence of heart failure in patients with type 2 diabetes mellitus. Results of the prospective DIABET-IC study
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes: a risk factor in heart disease

The Event

Event poster

ESC Congress 2024

2 September 2024 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on vascular function and liver steatosis in diabetes
thumbnail
Congress Session
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?
thumbnail
Congress Presentation
Impact of SGLT2 inhibitors on liver-related outcomes in patients with heart failure - a population-based study in HK

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources